Skip to main content
SpringerLink
Log in

Enhanced release of vasoconstrictors

  • Conference paper
Portal Hypertension in the 21st Century

  • 164 Accesses

Abstract

Increased resistance to portal blood flow is the primary factor in the pathophysiology of portal hypertension, and may occur at any site within the portal venous system. In cirrhosis, increased intrahepatic vascular resistance is the consequence of the distortion of the liver vascular architecture caused by fibrosis, scarring and nodule formation. Careful pathological studies have suggested that thrombosis of medium and small portal and hepatic veins occurs frequently in cirrhosis, and that these events may be important in causing further progression of cirrhosis and worsening portal hypertension1. In addition, the active contraction, in response to several agonists, of different contractile cell types in the liver promotes a further increase in intrahepatic resistance2. It has been claimed that this dynamic and reversible component may represent up to 40% of the increased intrahepatic vascular resistance in cirrhosis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology. 1995;21:1238–47.

    PubMed  CAS  Google Scholar 

  2. Bathal PS, Grossmann HJ. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol. 1985;1:325–9.

    Article  Google Scholar 

  3. Zhang JX, Pegoli W, Clemens MG. Endothelin-1 induces direct constriction of hepatic sinusoids. Am J Physio J. 1994; 266:G624–32.

    CAS  Google Scholar 

  4. Kawada N, Tran-Thi TA, Klein H, Decker K. The contraction of hepatic stellate (Ito) cells stimulated with vasoactive substances. Possible involvement of endothelin 1 and nitric oxide in the regulation of the sinusoidal tonus. Eur J Biochem. 1993;213:815–23.

    Article  PubMed  CAS  Google Scholar 

  5. Kaneda K, Ekataksin W, Sogawa M, Matsumura A, Cho A, Kawada N. Endothelin-1-induced vasoconstriction causes a significant increase in portal pressure of rat liver: localized constrictive effect on the distal segment of preterminal portal venules as revealed by light and electron microscopy and serial reconstruction. Hepatology. 1998;27:735–47.

    Article  PubMed  CAS  Google Scholar 

  6. Rubanyi GM, Botelho LH. Endothelins. FASEB J. 1991;5:2713–20.

    PubMed  CAS  Google Scholar 

  7. Clozel M, Gray GA, Breu V, Loffler BM, Osterwalder R. The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. Biochem Biophys Res Commun. 1992;186:867–73.

    Article  PubMed  CAS  Google Scholar 

  8. Asbert M, Gines A, Gines P et al. Circulating levels of endothelin in cirrhosis. Gastroenterology. 1993;104:1485–91.

    PubMed  CAS  Google Scholar 

  9. Moller S, Gulberg V, Henriksen JH, Gerbes AL. Endothelin-1 and endothelin-3 in cirrhosis: relations to systemic and splanchnic haemodynamics. J Hepatol. 1995;23:135–44.

    Article  PubMed  CAS  Google Scholar 

  10. Gerbes AL, Moller S, Gulberg V, Henriksen JH. Endothelin-l and-3 plasma concentrations in patients with cirrhosis: role of splanchnic and renal passage and liver function. Hepatology. 1995;21:735–9.

    PubMed  CAS  Google Scholar 

  11. Bernardi M, Gulberg V, Colantoni A, Trevisani F, Gasbarrini A, Gerbes AL. Plasma endothelin-l and-3 in cirrhosis: relationship with systemic hemodynamics, renal function and neurohumoral systems. J Hepatol. 1996;24:161–8.

    Article  PubMed  CAS  Google Scholar 

  12. Trevisani F, Colantoni A, Gerbes AL et al. Daily profile of plasma endothelin-l and-3 in pre-ascitic cirrhosis: relationships with the arterial pressure and renal function. J Hepatol. 1997;26:808–15.

    Article  PubMed  CAS  Google Scholar 

  13. Pinzani M, Milani S, De Franco R et al. Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology. 1996;110:534–48.

    Article  PubMed  CAS  Google Scholar 

  14. Gandhi CR, Sproat LA, Subbotin VM. Increased hepatic endothelin-1 levels and endothelin receptor density in cirrhotic rats. Life Sci. 1996;58:55–62.

    Article  PubMed  CAS  Google Scholar 

  15. Zhang JX, Pegoli Jr W, Clemens MG. Endothelin-l induces direct constriction of hepatic sinusoids. Am J Physiol (Gastrointest Liver Physiol). 1994;29:G264–632.

    Google Scholar 

  16. Rockey DC, Weisiger RA. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology. 1996;24:233–40.

    Article  PubMed  CAS  Google Scholar 

  17. Elliot AJ, Vo LT, Grossman VL, Bhathal PS, Grossman HJ. Endothelin-induced vasoconstriction in isolated perfused liver preparations from normal and cirrhotic rats. J Gastroenterol Hepatol. 1997;12:314–18.

    Article  PubMed  CAS  Google Scholar 

  18. Zhang JX, Bauer M, Clemens MG. Vessel-and target cell-specific actions of endothelin-l and endothelin-3 in rat liver. Am J Physiol. 1995;269:G269–77.

    PubMed  CAS  Google Scholar 

  19. Reichen J, Gerbes AL, Steiner MJ, Sagesser H, Clozel M. The effect of endothelin and its antagonist Bosentan on hemodynamics and microvascular exchange in cirrhotic rat liver. J Hepatol. 1998;28:1020–30.

    Article  PubMed  CAS  Google Scholar 

  20. Poo lL, Jimenez W, Maria MR et al. Chronic blockade of endothelin receptors in cirrhotic rats: hepatic and hemodynamic effects. Gastroenterology. 1999;116:161–7.

    Article  PubMed  CAS  Google Scholar 

  21. Ballet F, Chretien Y, Rey C, Poupon R. Differential response of normal and cirrhotic liver to vasoactive agents. A study in the isolated perfused rat liver. J Pharmacol Exp Ther. 1988;244:283–9.

    PubMed  CAS  Google Scholar 

  22. Graupera M, Garcia-Pagan lC, Abraldes JG et al. Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers. Hepatology. 2003;37:172–81.

    Article  PubMed  CAS  Google Scholar 

  23. Xing M, Insel PA. Protein kinase C-dependent activation of cytosolic phospholipase A2 and mitogen-activated protein kinase by alpha 1-adrenergic receptors in Madin-Darby canine kidney cells. J Clin Invest. 1996;97:1302–10.

    Article  PubMed  CAS  Google Scholar 

  24. Athari A, Hanecke K, Jungermann K. Prostaglandin F2 alpha and D2 release from primary Ito cell cultures after stimulation with noradrenaline and ATP but not adenosine. Hepatology. 1994;20:142–8.

    PubMed  CAS  Google Scholar 

  25. Schneider A W, Kalk JF, Klein CPo Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology. 1999;29:334-9.

    Google Scholar 

  26. Gonzalez-Abraldes J, Albillos A, Banares R et al. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology. 2001;121:382–8.

    Article  PubMed  CAS  Google Scholar 

  27. Debernardi-Venon W, Barletti C, Alessandria C et al. Efficacy of irbesartan, a receptor selective antagonist of angiotensin II, in reducing portal hypertension. Dig Dis Sci. 2002;47:401–4.

    Article  PubMed  CAS  Google Scholar 

  28. Graupera M, Garcia-Pagan JC, Titos E et al. 5-Lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: a possible role of cysteinyl-leukotrienes. Gastroenterology. 2002;122:387–93.

    Article  PubMed  CAS  Google Scholar 

  29. Back M, Norel X, Walch L et al. Prostacyclin modulation of contractions of the human pulmonary artery by cysteinyl-leukotrienes. Eur J Pharmacol. 2000;401:389–95.

    Article  PubMed  CAS  Google Scholar 

  30. Titos E, Claria J, Bataller R et al. Hepatocyte-derived cysteinyl leukotrienes modulate vascular tone in experimental cirrhosis. Gastroenterology. 2000;119:794–805.

    Article  PubMed  CAS  Google Scholar 

  31. Aleixandre de Artifiano A, Lopez-Miranda Gonzalez V. Endothelial dysfunction and hypertensive vasoconstriction. Pharmacol Res. 1999;40:113–24.

    Article  Google Scholar 

  32. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest. 1997;100:2153–7.

    Article  PubMed  CAS  Google Scholar 

  33. Fu-Xiang D, Jameson M, Skopec J, Diederich A, Diederich D. Endothelial dysfunction of resistance arteries of spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1992;20(Suppl. 12):S190–2.

    Article  PubMed  CAS  Google Scholar 

  34. Wilcox JN, Subramanian RR, Sundell CL et al. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscler Thromb Vase Biol. 1997;17:2479–88.

    Article  CAS  Google Scholar 

  35. Ge T, Hughes H, lunquero DC, Wu KK, Vanhoutte PM, Boulanger CM. Endotheliumdependent contractions are associated with both augmented expression of prostaglandin H synthase-l and hypersensitivity to prostaglandin H2 in the SHR aorta. Circ Res. 1995;76:1003–10.

    Article  PubMed  CAS  Google Scholar 

  36. Mayhan WG. Role of prostaglandin H2-thromboxane A2 in responses of cerebral arterioles during chronic hypertension. Am J Physiol. 1992;262:H539–43.

    PubMed  CAS  Google Scholar 

  37. Mayhan WG, Simmons LK, Sharpe GM. Mechanism of impaired responses of cerebral arterioles during diabetes mellitus. Am J Physiol. 1991;260:H319–26.

    PubMed  CAS  Google Scholar 

  38. Lerman A, Holmes DR Jr, Bell MR, Garratt KN, Nishimura RA, Burnett JC Jr. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation. 1995;92:2426–31.

    Article  PubMed  CAS  Google Scholar 

  39. Tagawa H, Tomoike H, Nakamura M. Putative mechanisms of the impairment of endothe-lium-dependent relaxation of the aorta with atheromatous plaque in heritable hyperlipidemic rabbits. Circ Res. 1991;68:330–7.

    Article  PubMed  CAS  Google Scholar 

  40. Gupta TK, Toruner M, Chung MK, Groszmann RJ. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology. 1998;28:926–31.

    Article  PubMed  CAS  Google Scholar 

  41. Bellis L, Berzigotti A, Abraldes JG et al. Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis. Hepatology. 2003;37:378–84.

    Article  PubMed  CAS  Google Scholar 

  42. Bosch J, Garcia-Pagan JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol. 2000;32(Suppl. 1):141–56.

    Article  PubMed  CAS  Google Scholar 

  43. Graupera M, Garcia-Pagan JC, Pares M, Abraldes JG et al. Cyclooxyenase-l inhibition corrects endothelial dysfunction in cirrhotic rat livers. J Hepatol. 2003;39:521.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, Villaroel 170, 08036, Barcelona, Spain

    Juan Carlos García-Pagán

Authors
  1. Juan Carlos García-Pagán
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Yale University School of Medicine, New Haven, CT, USA

    R. J. Groszmann

  2. Hepatic Hemodynamic Laboratory Liver Unit, Hospital Clinic, University of Barcelona, Spain

    J. Bosch

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media Dordrecht

About this paper

Cite this paper

García-Pagán, J.C. (2004). Enhanced release of vasoconstrictors. In: Groszmann, R.J., Bosch, J. (eds) Portal Hypertension in the 21st Century. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-1042-9_10

Download citation

  • DOI: https://doi.org/10.1007/978-94-007-1042-9_10

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-3774-7

  • Online ISBN: 978-94-007-1042-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation